Within the framework of the 2022 Innovation Week organized by the Mexican Association of Pharmaceutical Research Industries (AMIIF), Rodrigo Ruiz, president of the organization and COO of the Mexican pharmaceutical company Stendhal Pharma, explained how the pandemic has caused innovative therapies to be accepted in less time to be used by Mexican patients.
In just two years, 36 vaccines against Covid-19 were approved, under different specifications on their use, by at least one country or regulatory agency, in addition to various treatments.
“The pandemic made it clear that the sector needed to be more flexible and streamline regulatory processes in order to be able to innovate with treatments that are of value to patients, in an effective way. It also helped strengthen collaboration between pharmaceutical companies, the government and society, with more efficient clinical studies, optimization of research and development processes to face the pandemic while taking care of other ailments”, commented Rodrigo Ruiz.
One of the main themes of innovation that Rodrigo Ruiz referred to is cross-pollination and the transforming power that this could have in health technologies, that is, in the importance of learning from others, with respect to technology and its applications in other industries and sectors to adapt it to health issues.
“Mexico has the potential to be a clinical research hub in Latin America, but we need a common understanding of this opportunity and we work on that every day. There is an urgent need to promote the creativity that new generations bring to the sector so that changes are generated for the benefit of all patients in the country. After the crisis we faced due to the Covid-19 pandemic, we learned the power of alliances and we have confirmed that the future of medical care lies in working on the development of technology”, added Rodrigo Ruiz.
At the beginning of 2022, Rodrigo Ruiz announced that Stendhal Pharma will sign various alliances this year with international biopharmaceuticals in order to offer innovative therapies for Mexican patients and patients from other countries in Central America, the Caribbean and South America, such as with the North American laboratory Alnylam .
With this partnership, Stendhal will market Alnylam’s RNA Interference (RNAi) therapy, a technology that won the Nobel Prize in Medicine or Physiology, for the treatment of rare diseases such as Hereditary Amyloidosis and Acute Hepatic Porphyria in Mexico, Costa Rica, Guatemala, Panama and the Dominican Republic.
One of Stendhal’s main objectives is to offer innovative medicines, seeking to provide solutions to specific problems that affect human health. The company offers the best health care products, guaranteeing excellence in research, development, production and marketing.
We would like to thank the author of this article for this incredible web content
Due to a pandemic, Mexicans will have access to innovative therapies more quickly